Neurotech International Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.22%

Neurotech International Ltd (NTI) has an Asset Resilience Ratio of 0.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$15.00K
≈ $10.61K USD Cash + Short-term Investments

Total Assets

AU$6.81 Million
≈ $4.82 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Neurotech International Ltd's Asset Resilience Ratio has changed over time. Check NTI strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Neurotech International Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Neurotech International Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$15.00K 0.22%
Total Liquid Assets AU$15.00K 0.22%

Asset Resilience Insights

  • Limited Liquidity: Neurotech International Ltd maintains only 0.22% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Neurotech International Ltd Industry Peers by Asset Resilience Ratio

Compare Neurotech International Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 2.34%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%

Annual Asset Resilience Ratio for Neurotech International Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Neurotech International Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 0.46% AU$15.00K
≈ $10.61K
AU$3.24 Million
≈ $2.29 Million
-77.44pp
2024-06-30 77.91% AU$9.52 Million
≈ $6.73 Million
AU$12.21 Million
≈ $8.64 Million
+39.95pp
2023-06-30 37.96% AU$2.02 Million
≈ $1.43 Million
AU$5.31 Million
≈ $3.76 Million
+37.21pp
2022-06-30 0.74% AU$15.00K
≈ $10.61K
AU$2.02 Million
≈ $1.43 Million
-95.69pp
2021-06-30 96.43% AU$4.83 Million
≈ $3.42 Million
AU$5.01 Million
≈ $3.54 Million
+48.40pp
2018-06-30 48.03% AU$2.21 Million
≈ $1.57 Million
AU$4.61 Million
≈ $3.26 Million
+3.50pp
2017-06-30 44.53% AU$2.21 Million
≈ $1.56 Million
AU$4.95 Million
≈ $3.50 Million
+41.28pp
2016-06-30 3.25% AU$500.00K
≈ $353.78K
AU$15.37 Million
≈ $10.88 Million
--
pp = percentage points

About Neurotech International Ltd

AU:NTI Australia Biotechnology
Market Cap
$13.99 Million
AU$19.77 Million AUD
Market Cap Rank
#26170 Global
#1179 in Australia
Share Price
AU$0.02
Change (1 day)
-11.76%
52-Week Range
AU$0.01 - AU$0.02
All Time High
AU$0.48
About

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more